Lentivirus News and Research

RSS

Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Researchers use antigenic cartography to analyze cross-reactivity patterns of eight groups of human sera on a panel of SARS-CoV-2 variants.

2 Feb 2022

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.

1 Feb 2022

Exploring beta-coronavirus neutralization by vaccine-induced murine antibody WS6

In a new study, researchers evaluated the neutralizing antibody titers in mice vaccinated with messenger ribonucleic acid (mRNA) encoding SARS-CoV-2 spike (S) protein.

1 Feb 2022

Children and adolescents respond as well or better than adults to mRNA-1273 COVID vaccination

A recent study assesses the neutralization efficacy of the mRNA-1273 vaccine against the SARS-CoV-2 Omicron variant in children, adolescents, and adults.

30 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

In a new study, researchers analyzed the neutralization of SARS-CoV-2 Omicron and D614G variants before and after subjects received COVID-19 booster vaccinations.

18 Jan 2022

Latest tools for COVID-19 Omicron variant research

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.

From AMS Biotechnology 11 Jan 2022

Strategy for capturing SARS-CoV-2 through functionalized cellulose materials

Researchers from Northeastern University have developed a new, more cost-effective method for immobilizing SARS-CoV-2.

10 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

A new study shows that although the Omicron variant exhibits significant immune escape compared to other SARS-CoV-2 variants, antibody neutralization can be largely restored with booster doses of mRNA vaccines.

22 Dec 2021

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

Scientists have recently reported the efficacy of carrageenan against both the SARS-CoV-2 original strain as well as the Alpha, Beta, Gamma, and Delta VOCs.

13 Dec 2021

Custom Biofluid & Tissue Procurement Service

Global provider of human and animal biospecimens - AMSBIO offers a custom procurement service enabling researchers to source specific biofluid and tissue samples which are not already available in their extensive biorepository.

From AMS Biotechnology 1 Dec 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

A new study has described the molecular basis of the neutralization potency and breadth of nanobodies.

16 Nov 2021

Novel tetravalent antibodies for the ultrapotent and broad neutralization of SARS-CoV-2 variants

Researchers from the University of Toronto set out to create a new tetravalent antibody that could bind with enough potency that it could remain effective against VOCs.

9 Nov 2021

Convalescent plasma post-vaccination increases binding and neutralizing antibodies against SARS-CoV-2 variants

A recent study assesses the boost in antibodies against SARS-CoV-2)variants post-vaccination in plasma samples from previously infected COVID-19 patients.

7 Nov 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Increased transmission in open spike conformations of SARS-CoV-2 variants

Researchers from Yale University and the University of Texas have collaborated to investigate mutations in some VOCs.

14 Oct 2021

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

It is demonstrated that palmitoylation of the first five cysteine residues of the C-terminal domain of the SARS-CoV-2 spike protein facilitates cell entry and the formation of syncytia.

11 Oct 2021